US $2.6 billion, 10 which represents a 145% increase over the estimate the center made in 2003. 11 However, an independent evaluation of research and development at that time stated that a more realistic estimate would correspond to less than 10% of what was claimed. 12 For many drugs, the preclinical phase of research is funded by academia, which is mostly financed with taxpayers' money. 13, 14 In the case of anticancer drugs, 85% of basic research is supported this way, whereas pharmaceutical companies spend only 1.3% of their revenues on this initial phase of drug development. 15 Approximately 5% to 13% of drug companies' expenses occur at the clinical trial level, whereas 20% to 45% are allocated to advertisement, including marketing and administration. 16 In 2013, a group of 100 expert oncologists concluded the following: "Of the many complex factors involved, price often seems to follow a simple formula: start with the price for the most recent similar drug on the market and price a new drug within 10-20% of that price (usually higher)."
17 Surprisingly, various industry insiders have corroborated this information. 18 Ultimately, drug prices seem to be set at whatever the market will bear.
In the market, cancer drugs behave differently from medications for other chronic diseases. For example, due to the life-threatening nature and complexity of cancer, regardless of rising costs, there is a willingness among patients and physicians to accept and pay high prices for cancer drugs. In other words, the demand for cancer drugs is largely inelastic, or insensitive to changes in price. 19 Additionally, high-cost cancer medications are protected by patents, which make them expensive single-source monopoly products. 19, 20 Also, as the great majority of cancers are incurable and the beneficial effect of most drugs is short and finite, the approval of a new drug does not necessarily mean that others available are no longer required. In fact, each new approved agent is frequently used either in combination, or sequentially, with existing drugs. 21, 22 Thus, despite the fact that various anticancer drugs may be approved for similar cancer indications, pharmaceutical companies usually avoid price competition. 16 Additionally troubling is the fact that many new cancer medications can offer statistically significant gains, which may not necessarily translate into clinically meaningful benefits. With a sufficiently large clinical trial sample size, a small prolongation of survival of days or weeks can achieve statistical significance. 21 
EVALUATING COST-EFFECTIVENESS AND VALUE OF CANCER TREATMENT
Once a medication has shown efficacy in a clinical trial, organizations such as the US Food and Drug Administration and the European Medicines Agency (EMA) evaluate its benefits and risks independently of its price to grant regulatory approval. Currently, the rising cost of health technologies (including drugs, medical devices, vaccines, and procedures), paired with limited health care budgets and competing societal priorities, is pushing public and private institutions worldwide to seek mechanisms that allow health systems to perform with greater efficiency and equity. Proof thereof is the fact that the "value" of a cancer treatment (i.e., assessments of its cost, efficacy, and safety) 23 is increasingly being used when deciding if a new technology should be incorporated into the preventive, diagnostic, or therapeutic repertoire of a health system. Both the American Society of Clinical Oncology 24 and the European Society for Medical Oncology 25 have recently launched frameworks to define the value of cancer care in different clinical scenarios.
Various methodologies are employed by health economists to perform cost-effectiveness analyses. Two key metrics are quality-adjusted life-years (QALYs) and incremental cost effectiveness ratio (ICER). QALYs refer to the number of years of life that would be gained by an intervention, adjusted for quality of life (QoL), whereby QALY 5 life expectancy 3 QoL. QoL ranges from 0.0 to 1.0, exhibiting maximum value in perfect health. It is affected by the efficacy and toxicity of the therapy and determined through standardized tools that assess vision, hearing, mobility, cognition, speech, pain, dexterity, and emotion. As a result, gaining 1 year of life with a QoL of 0.5 equates to a gain of half a year in perfect health (i.e., half a quality-adjusted life year: QALY 5 1 3 0.5 5 0.5 years). 21, 24, 26 The ICER is defined as the ratio of additional cost to incremental benefit of an intervention and is expressed as the cost per QALY. For example, suppose that the standard treatment for a certain condition costs $2000 and provides 0.5 QALYs, and a new treatment is priced at $10,000 and provides 1.5 QALYs. To calculate the ICER, the difference in costs between the 2 treatments is divided by the difference in QALYs between the 2 treatments: ICER 5 ($10,000 -$2000)/(1.5 -0.5) 5 $8000 per QALY gained. The obtained ICER is then compared against a threshold deemed acceptable by a designated entity. 21, 24 For example, the WHO proposes using the wealth of a country or per capita GDP when deciding on the economic limits for funding an intervention. A drug with an ICER that is lower or equal to the per capita GDP would be regarded as very cost-effective, one with an ICER 1 to 3 times GDP would be deemed cost-effective, and one with an ICER more than 3 times the GDP would be considered cost-ineffective. 27 
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Frequently, these cost-effectiveness evaluations form part of a process of health technology assessment (HTA), which is defined as the "systematic evaluation of medical technologies regarding their effectiveness, appropriateness, and efficiency, as well as social and ethical aspects and implications." 28 These evaluations aim to provide structured, evidence-based input to policymaking on health care priority setting, reimbursements, and coverage decisions to achieve the best value in the allocation of public resources. 29 In light of these objectives, HTA has been called "the bridge between evidence and policymaking." 30 HTA is performed by public or private organizations, through regulatory bodies and advisory committees. These entities are composed of a variety of stakeholders including physicians, academics, pharmacists, health economists, insurance and industry representatives, and patients. 31 HTA also importantly contributes to the improvement of care through scientific knowledge, particularly by supporting the development or updating of clinical practice guidelines and standards of health service provision. 32, 33 Probably the most well-known example of a regulatory body performing HTA is the National Institute for Health and Care Excellence (NICE), which was set up by the UK government in 1999 as a formal independent organization with the mission of integrating clinical and economic analyses to determine whether it is worth spending public money on a medicine to be accessible through the National Health Service. 24 This institution uses an ICER cutoff of £20,000 to £30,000 per QALY (a little less than US $50,000), above which it is unlikely it will pay for a drug. Life-extending treatments (>3 months) for a small population of patients with short life expectancy (<24 months) can exceed NICE's costeffectiveness cutoff of £30,000. 34 Because NICE presents its documents for public scrutiny, it is considered one of the most transparent and visible agencies worldwide. NICE has 3 centers of excellence: HTA, Public Health, and Clinical Practice Guidelines. 35 This institution has significantly contributed to the globalization of HTA. In 2008, NICE established an international division, which helps foreign policy makers with tailoring guidelines to their own settings, performing cost-effectiveness analyses, training human resources and policy makers, and implementing independent and transparent resource allocation processes prepared to overcome lobbying and other drug approval pressures. 36 HTA agencies are not flawless, and if evaluations are not performed diligently, there is the risk of harming patients or the public. For example, decisions by NICE, as well as those of its international counterparts, have generated significant controversy around delayed approval for useful drugs and the use of arbitrary economic thresholds. [37] [38] [39] [40] However, as a commentary from the Mayo Clinic stated: "imperfections in cost-effectiveness analyses should not be an excuse for inaction." 21 SPECIFIC CHALLENGES TO LATIN AMERICAN HEALTH CARE SYSTEMS Despite a lower incidence of cancer compared with the United States and Europe, cancer mortality rates in Latin America are higher. The all-cancer mortality-to-incidence ratio for Latin America is 0.59, compared with 0.35 in the United States. 41 This gap is driven largely by more advanced stage of disease at initial presentation, as well as barriers to access to care. By 2030, the number of cancer cases is estimated to increase by 35% in South America and by 42% in Central America and Mexico, posing an enormous challenge to Latin American health care systems, which are typically highly fragmented and underfunded. 41 Regardless of the fact that cancer in low-and middle-income countries (LMICs) accounts for 77% of the disability-adjusted life-years (DALYs) lost worldwide, 42 only 5% of global resources for cancer are consumed in the developing world. 43 Furthermore, only a minor percentage of national GDPs in Latin America (ranging from less than 5% in Venezuela and Peru to more than 10% in Costa Rica and Cuba) is destined for use in health care. 44 On average, the percentage of Latin American GDP devoted to health is 7.7%, compared with 18% in the United States. The overall mean expenditure per new cancer patient in the region is US $7.92 compared with US $183, US $244, and US $460 spent by the United Kingdom, Japan, and the United States, respectively. The overall cost of cancer care has been calculated to represent 0.12% of gross national income per capita in South America versus 0.51%, 0.6%, and 1.02% in the United Kingdom, Japan, and the United States, respectively. 41 These statistics highlight the striking inequity and shortage of resources for cancer care and control in Latin America.
Among 37 new cancer drugs launched worldwide between 2009 and 2013, only 17 are available in Mexico and 10 in Brazil, the leading so-called "pharmerging" countries in the region. 45 However, even if more drugs do become available, these are usually only accessible for a privileged minority of the population enrolled in private insurance programs. Frequently, public insurance in many countries in the region exclude anticancer essential drugs or restrict their use for some indications. For example, in Brazil, Chile, and Peru, trastuzumab is not covered by the public health systems for treatment of HER2-positive breast cancer in the metastatic setting. 46 Drug prices, especially from single sources, vary dramatically among nations, 22, 47, 48 and Latin America is no exception. For example, in 2012, the price of a year's worth of adjuvant trastuzumab for breast cancer in Latin America ranged from US $25,636 in Uruguay to US $61,302 in Brazil. 49 In fact, several anticancer drugs are more highly priced in many LMICs than in high-income nations. 50, 51 Of importance, no relationship exists between pharmaceutical prices in LMICs and national GDPs. 51 In 2011, a study that compared prices of highcost drugs, including 8 cancer-targeted therapies, found that the United Kingdom paid less for these drugs than Argentina, Brazil, Paraguay, and Uruguay, in all cases. Specifically, these drugs in the United Kingdom cost 29% to 75% of what they cost in Argentina. The same study concluded that, at that time, Argentina could have saved 64% of what was spent on high-cost medications if the country had bought each drug from the country that was purchasing them at the lowest price. 50 A recent study explored the cost-effectiveness of 12 months of adjuvant trastuzumab for HER2-positive breast cancer in 7 Latin American countries: Argentina, Bolivia, Brazil, Colombia, Chile, Peru, and Uruguay. 52 Following the recommendation of the WHO, 3 times the GDP per capita was established as the threshold below which an intervention could be considered cost-effective. The investigators found that the ICER, expressed in terms of times the GDP per capita per QALY gained, ranged between 3.6 in Uruguay to 35.5 in Bolivia. This calculation means that although cost-effective in other settings, trastuzumab, as currently priced, is not cost-effective in Latin America using the WHO threshold. It was concluded that the price of trastuzumab would need to drop between 69.6% and 94.9% to become cost-effective in these countries.
Access to health is recognized as a constitutional right in most Latin American countries. 19, 53, 54 Based on this legislated perspective, and encouraged by the media, citizens unable to access therapies through regular channels of the health system increasingly resort to filing legal suits against the government, citing their constitutional right to health care. 53 The judiciary frequently finds itself ruling on financing a specific drug for a particular patient. This trend toward judicialization of medicine has varying grades and has an impact in most Latin American countries. For example, in 2009, the Colombian Ministry of Health estimated that the direct cost of litigation only in the contributive insurance program (directed at those formally employed) reached US $300 million. In Brazil, 240,000 legal patient claims were made in 2010, accounting for US $550 million. In the Brazilian state of São Paulo alone, US $380 million were paid on claims for high-cost medications. 55 In general, Latin American judicial authorities tend to rule in favor of patients' claims 19 : a systematic review including 30 right-to-health litigation studies found that plaintiffs were favored in the great majority of cases: in Colombia (75%-87%), Costa Rica (89.7%), and Brazil (70%-100%). 56 These litigations, steadily overruling national funding policies, can undermine the sustainability of public health care systems by diverting resources away from rational use for the collective benefit of the general public. 53, 57 POTENTIAL SOLUTIONS In view of this background, we propose a set of potential solutions to help control and reduce the high cost of cancer drugs in Latin America.
Increase and Redistribution of Budget for Cancer Care
Cancer is a burgeoning health priority in Latin America, and adequate public funding is needed. Having acknowledged the existence of inequities, a rise in public spending on cancer is desirable. However, even when increasing the budget, its efficient distribution is necessary to make funding available for expensive treatments when required. Implementing preventive measures, health education programs, and early diagnosis strategies, as well as improving care at the end of life (to avoid futile treatment) and reducing medical imaging costs, are just some examples of effective interventions to accomplish these objectives. 20, 58 Strengthening cost-effectiveness analyses and health technology assessment
In the context of underfunded health care systems, it becomes imperative in Latin America to allocate the limited budget available to technologies that provide the equitable and best value for patients without neglecting other important interventions. Within the region, costeffectiveness evaluations and HTA are relatively new processes, with different grades of implementation and development among countries. 23 Mapping HTA development within a country is methodologically complex and implies evaluations of both the degree of institutionalization and of the HTA process itself (including identification, priority setting, assessment, appraisal, reporting, timely dissemination, and implementation in policy and practice). 59 In addition, when establishing these agencies in Latin America, numerous barriers have to be overcome. These include fragmentation of health care systems; shortage of resources, most importantly human capital, knowledge, and expertise; lack of local data from cancer registries; and weak institutional structures susceptible to pressure from suppliers, lobbyists, and other unwanted influences. [59] [60] [61] A systematic evaluation of the status of HTA in Latin America is lacking. Nevertheless, significant progress has been made recently. 62 The [69] [70] [71] The Argentinean Ministry of Health authorities created the UCEETS to ascertain the cost and impact of health technologies. Its duties include the development of an annual plan of inclusion and prioritization of new technologies; the evaluation of previously established technologies; and the generation of HTA products, particularly clinical practice guidelines and technical reports. Another institutional body dedicated to HTA in Argentina is the IECS, which was designed as a "Collaborating Centre of Health Technology Assessment" by PAHO/WHO in 2013 and acts as a guide to other countries in the region, such as Bolivia, Panama, and Peru. 72 In Brazil, the ultimate decision to fund new technologies in the public sector lies within the domain of the Ministry of Health and is based, by law, on the recommendations of CONITEC. This latter entity is also in charge of keeping the list of essential drugs up to date. The executive secretary of CONITEC, operated by the Department of Management and Incorporation of Health Technologies, coordinates CONITEC activities and is responsible for the emission of technical reports taking into consideration scientific evidence, economic evaluation, and impact of each technology assessed. 73 As a result of their analysis, trastuzumab was incorporated into the treatment of early-stage and locally advanced HER2-positive breast cancer, but only after a price reduction of 44.8% had been negotiated and 2 new formulations (60 and 150 mg) had been provided. 74 In Mexico, HTA has also been adopted as a national strategy, which is required for the incorporation of new technologies in the public and social security system. CENETEC is the HTA agency of the Mexican Ministry of Health. 49 In the case of Uruguay, the National Therapeutic Formulary (FTM) commission of the Ministry of Health defines and reviews the list of essential medicines for every health institution, private or public. Scientific evidence and cost-effectiveness evaluations, as well as budget impact analyses ensuring financial sustainability, are required to incorporate technologies by the FTM. The FNR is a non-state public institution that finances the FTM and aims to ensure equitable access to highly specialized medical procedures and expensive drugs. 75 Importantly, Uruguay has tracked the outcomes and impact of various approved medications using real-world registries since 2010. 76 Despite the progress achieved within the region, experience with HTA is still limited to few countries. When facing the challenge of formally developing a systematic and transparent arms-length process for HTA in Latin American countries, many lessons can be learned from prior international experiences, particularly from Latin America. 77 In addition, to be able to adapt HTA reports from other countries, national and regional capacities for conducting economic impact studies are urgently needed.
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Collective Negotiation and Procurement
As discussed, the price of high-cost medications often varies between and even within countries in Latin America. 19, 50 This is partly due to the fragmentation of the demand and the asymmetry of information among buyers. 19 In this regard, joint purchasing as a region would offer individual countries the opportunity to participate in collective, multinational transactions that enhance their negotiation power with drug companies while potentially decreasing administrative costs. 19, 43 Single-buyer negotiation therefore affords the chance of drugs becoming available at fixed lower prices. Ideally, these joint transactions require that the participants have comparable policies and decision-making frameworks that facilitate routine collaboration. 79 
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Cancer April 15, 2017 In September 2015, countries from the intergovernmental regional organizations UNASUR and MERCO-SUR (which together include the countries of Argentina, Bolivia, Brazil, Colombia, Chile, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela) endorsed the creation of a committee for joint bargaining and purchase of high-cost medications. 80 During a successful initial round of negotiations with a number of pharmaceutical companies, the health ministers agreed to purchase darunavir-an antiretroviral agent for the treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS)-at a price significantly less than the lowest price available previously in the region, resulting in collective cost savings of around US $20 million for participating countries. The plan is to purchase anticancer drugs through this joint bargaining strategy. 81 In addition, the WHO's Model List of Essential Medicines 5 assists policymakers in reducing costs by helping them in the challenging task of identifying those medicines that will have the greatest impact on public health and therefore allocating limited resources effectively. Inclusion of a drug on the WHO list represents a crucial step for improving its affordability, 82 because it serves as a powerful tool to be used by the region for price negotiation and procurement with pharmaceutical companies, as well as by nongovernmental organizations, professional associations, and patient organizations to pressure governments and payers.
Creation of Resource Funds
A strategy closely linked to joint bargaining and procurement is the creation of international funds that facilitate the acquisition of medicines at lower prices due to largevolume purchases. This strategy is especially beneficial to smaller, less developed countries that otherwise would have to pay higher prices for small quantities. An interesting example is the Revolving Fund of the PAHO. Member states pool their national resources and PAHO acts as a procurement agent, negotiating annual arrangements with the suppliers on behalf of the Member States. As a result, high-quality vaccines have been procured at 4.25% of their net cost. 83 For example, in 2015 the bivalent Human Papilloma Virus (HPV) vaccine price for LMICs in Latin America was US $8.50 per dose 84 compared with a cost of US $107 per dose in the United States. 85 
Differential Pricing Policies
Differential or tiered pricing in health care consists of stratifying a service or drug price in relation to average national income and willingness to pay. This means products will be more expensive in high-income countries and more affordable in LMICs. 37, 86 This strategy allows countries to limit the cost of new treatments and has successfully been applied to vaccines and HIV drugs. In the case of innovative cancer drugs, as a general rule, the industry carries on applying global pricing policies. 51 However, lately the threat of compulsory licensing has promoted the introduction of tiered pricing for selected cancer products from GlaxoSmithKline, Eli Lilly, Sanofi, and Roche. 60 From the pharmaceutical industry's perspective, the major risk of differential pricing is parallel importing of medications from poorer countries to wealthy ones, a situation which can be avoided by open discounts through controlled access programs. 60, 87 All strategies that increase affordability lead to higher levels of access and thus potentially create predictable markets with solid drug penetration that may ultimately generate better returns for drug companies. 16 
Use of Generics and Biosimilars Through Flexibility of Patent Laws
Whereas generics are both structural and therapeutic equivalents of chemical low-molecular weight drugs, biosimilars are therapeutically equivalent, but not identical, reproductions of an original biotherapeutic agent. To be approved, generic drugs must only demonstrate bioequivalence or a bioavailability (rate and extent of absorption) not significantly different from that of the reference drug. On the other hand, biosimilars will be required to demonstrate safety, purity, and potency for the intended use within clinical studies. 88 The use of generics and biosimilars offers cost-saving alternatives with comparable efficacy and safety to innovative new products for many indications in oncology, which is why their role in oncology is expected to attain great importance in the coming years. For example, it is estimated that the European Union and the United States will achieve annual savings of US $20.8 billion when patents of 3 antineoplastic monoclonal antibodies-rituximab, trastuzumab, and bevacizumab-expire in 2020. 89 Nevertheless, producing or buying generics and biosimilars is framed within strict regulations.
In 1994, the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement provided significant harmonization on pharmaceutical copyrights across national laws. TRIPS promotes innovation by compensating inventors of new drugs with government-granted monopolies known as patents, usually for 20 years. 90 If, in the interest of public health or national emergency, governments request a voluntary licensing on a patented medicine and this is denied, TRIPS enables countries to issue "compulsory licensing" for the manufacture of generic medications while patent protection is still in effect. 91 The Doha Declaration of 2001 further allows countries lacking drug production capacity to export medications produced under compulsory licensing and explicitly adds that "each Member [of the WTO] has the right to grant compulsory licenses and the freedom to determine the grounds upon which such licenses are granted." 92 In 2008, the Thai government issued compulsory licenses for docetaxel, letrozole, and erlotinib. The impact of this intervention was estimated to achieve savings of more than US $140 million over 5 years. 60, 93 In the case of imatinib, a compulsory license was about to be issued too; however, the manufacturer made a last-minute offer to the Thai government to deliver the medicine free to all patients under universal coverage, provided no compulsory license would be issued subsequently. 94 Likewise, in 2012, the Indian government awarded a compulsory license to manufacture a generic and cheaper alternative to the drug sorafenib. 21 In November 2014, a number of medical, academic, and nonprofit Colombian organizations requested a declaration of public interest to allow access to imatinib, 95 an unquestionably effective drug included in the WHO's Model List of Essential Medicines in 2015. 5 Whereas the Colombian gross national income per capita is US $12,910, 96 the median annual cost of Gleevec (Novartis brand name of imatinib) per patient in Colombia is approximately US $20,000. 97 The introduction of generic imatinib could potentially reduce expenses by 68% to 77%. 95 The Colombian government confronted open pressure from the Swiss government to reject the request, alleging flagrant disobedience of WTO TRIPS, being this deeply condemned by a large group of international nongovernmental organizations. 98 On June 17, 2016, after months of unsuccessful negotiations with Novartis, the Colombian Minister of Health finally issued Resolution 2475, declaring that it would be in the public interest for the government of Colombia to control the price of imatinib by setting a price limit on the drug. This constitutes the first step on the path toward compulsory licensing.
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The pharmaceutical industry claims, with little evidence, that not supporting copyrights in LMICs could have a negative impact on innovation because it may limit economic incentives, and that high prices granted by patents are indispensable for recouping investment in research and continuing investigation. 60 However, this argument is rendered invalid when considering the fact that around 80% of profit from cancer drugs comes from high-income countries in which compulsory licensing is rarely granted. 60 Indeed, various observational studies found that pharmaceutical companies whose products underwent compulsory licensing did not experience a decline in the rate of new drugs patented or in their innovation activity. 100, 101 On the other hand, there have been cases in which the use of compulsory licenses led to pressure by the pharmaceutical industry, loss of investment, and trade frictions with the countries producing patented drugs. 98, 102 In addition, compulsory licenses may raise efficacy and safety concerns of generics and biosimilars. 103 Among the new challenges posed by the current scientific revolution is the restructuring of patent law to achieve a new balance between public and private commercial interests. At least, as PAHO has stated, Latin American countries must ensure that the flexibilities of the TRIPS agreement are incorporated into their legal frameworks 53 and, when resorting to these mechanisms, it is preferable to do so within regional or subregional decisions to better deal with external pressures and avoid commercial sanctions. 19 
Evidence-Based Adaptation of Schemes of Treatment
Under conditions of extreme lack of access in which adherence to clinical guidelines applicable in high-income settings may not be financially feasible-and only after having exhausted other options-adapting treatment regimens in terms of dosage, frequency, or duration may be considered as an alternative strategy to improve access. 104, 105 As an example, a 9-week study of trastuzumab given concurrently with chemotherapy for breast cancer in the adjuvant setting (FinHER) suggested a similar benefit from much shorter administration of the monoclonal antibody. 106 A Cochrane meta-analysis reaffirmed this fact and concluded that this regimen did not differ in efficacy from studies of longer administrations of trastuzumab. 107 In light of these results, the Pharmaceutical Management Agency of New Zealand initially limited trastuzumab funding to cover only a 9-week treatment course 108 but eventually extended the funding to cover a 12-month treatment. 109 Remarkably, a Belgian cost-effectiveness analysis estimated that with this shorter scheme, it would be possible to treat 20% more patients with approximately one-fourth of the budget. 110 A scientific evidence-based approach-alongside resource-sensitive guidelines-to find less costly and therapeutically optimal alternatives is desirable.
Participation in Clinical Research
Latin America is emerging as an attractive setting for the conduct of clinical trials. The region has the regulatory framework and clinical infrastructure, as well as the number of patients, required to support high-quality research. Three Latin American countries-Brazil, Mexico, and Argentina-have been continuously ranked in the top 25 countries with high participation in pharmaceutical phase 2/3 clinical trials since 2007. 111 In 2012, 4.6% of worldwide cancer clinical trials were registered in Latin America, and 66% of them were sponsored by industry. 41 To some extent, participation in clinical trials allows access to both standard and investigational drugs that are otherwise not available in Latin America. However, this practice raises ethical issues related to economic conflicts of interest, the adequacy of informed consent, and the subsequent availability and affordability of approved therapies. 87 In fact, some argue that clinical trials conducted in Latin America rarely respond to the true public health priorities of the region and therefore may be distracting scientific resources from addressing cancer control issues of greater importance. 112 
WHAT CAN ONCOLOGISTS DO?
In 2012, 3 important physicians at the Memorial Sloan Kettering Cancer Center gained public attention when they declared in The New York Times that their center would abstain from including ziv-aflibercept, a new colon cancer drug, in the hospital formulary because of its unfavorable cost/benefit ratio. 113 A month later, the manufacturer, Sanofi, announced that it would offer a discount of 50% off the list price for this drug. 18, 114 This example shows that physicians advocating for underserved populations can do more than just act as spectators in this crisis. Instead of passively accepting what the industry provides, evidence should be analyzed critically in terms of real clinical benefit of novel agents to patients to safeguard rational medicine use. In this regard, physicians are responsible for developing national guidelines for cancer treatment and ensuring that cancer drugs with favorable cost/benefit ratios are included in national formularies. 115 A great proportion of oncologists are unfamiliar with the costs of treatment, and many feel inadequately trained to have cost discussions with patients. 58, 116 Particularly in LMICs, medical education-both primary and continuing-should be expanded to include critical review of evidence for interventions and to incorporate knowledge of costs and understanding of costeffectiveness analyses. 37 With the correct tools, doctors are in a strategic position to participate in discussions of economic priorities in health care and to influence all stakeholders. 16, 53, 117 CONCLUSION Innovative drugs have improved cancer outcomes significantly. Unfortunately, their skyrocketing prices have made them prohibitively expensive for most Latin American health care systems, as well as for other LMICs and even wealthier nations. The current oncology pricing structure is no longer sustainable and is threatening the economy of health systems. Even more alarming is the fact that many of the most expensive medicines do not yield meaningful clinical benefits to patients.
Much needs to be done to address this burgeoning crisis. Among the initial steps needed to rationally allocate limited resources is the incorporation of systematic and transparent cost-effectiveness analyses performed through independent, multidisciplinary committees or health technology agencies. On the basis of these evaluations, a number of complementary strategies can be devised, including, but not limited to, negotiation, collective bargaining, financing and procurement, differential pricing, increased use of evidence-based adapted treatment schemes and of quality generics and biosimilars through TRIPS flexibilities, and involvement in clinical trials.
We believe that the recommendations presented throughout this review are likely to be more effective within a synergistic regional approach. The problems and challenges of Latin American health care systems transcend national jurisdictional boundaries and should be faced collectively to optimize national capacities, share and compare best practices, and transfer scientific and technical capabilities.
Finally, all stakeholders, including the general public, must be aware that ensuring access to high-cost drugs, by itself, is unlikely to improve cancer mortality rates substantially in the region. Cancer care is a long continuum with multiple sites for intervention, ranging from access to care and prevention to primary treatment and supportive care. Access to high-cost cancer drugs represents only a small aspect of this challenge.
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